Skip to content

Adenoma–carcinoma and serrated pathways

TL;DR — Most colorectal adenocarcinomas arise through visible precursor lesions, but “the polyp–cancer sequence” comprises at least conventional adenoma and serrated routes with different morphology, molecular events and detection failures. The classic model linked early APC/WNT disruption, intermediate RAS activation and later tumor-suppressor loss to clonal progression, while modern genomics shows branching evolution rather than a mandatory order (Vogelstein 1988, PMID 2841597; Cancer Genome Atlas Network 2012, PMID 22810696). Serrated lesions are often proximal and subtle, commonly connect BRAF mutation to CpG-island methylation and sometimes MLH1 silencing/MSI (O'Brien 2015, PMID 25263173). Polypectomy reduces subsequent colorectal-cancer incidence and mortality, but risk after removal is not zero and depends on lesion features, completeness, colonoscopy quality and surveillance (Zauber 2012, PMID 22356322; He 2020, PMID 31302144). Prevention failure is therefore a chain of missed lesions, incomplete resection, inappropriate intervals and new biology—not one mechanism.

A plural model of carcinogenesis

Route Precursor Recurrent early biology Typical distribution Important prevention problem
Conventional adenoma Tubular, tubulovillous or villous adenoma APC/WNT dysregulation; later KRAS/TP53-pathway changes Throughout colon/rectum Missed advanced adenoma or incomplete excision
Serrated Sessile serrated lesion or traditional serrated adenoma BRAF or KRAS, CpG-island methylation; possible MLH1 loss SSL often proximal; TSA often distal Flat morphology, variable pathology and incomplete resection
Inflammation-associated Dysplasia in chronically inflamed mucosa Field inflammation and altered sequence Colitis-affected bowel Multifocal/invisible dysplasia
Inherited Syndrome-specific precursor burden Germline APC, MMR, MUTYH, polymerase or hamartomatous pathway Syndrome dependent Interval cancers despite surveillance

The routes overlap. A tumor can carry features from more than one classification, and anatomic site is an imperfect surrogate for molecular pathway (Sullivan 2022, PMID 35361330).

The conventional adenoma–carcinoma sequence

Vogelstein and colleagues examined genetic alterations across adenomas and cancers and proposed that tumor progression reflects accumulation of alterations, with the total combination more important than a rigid order (Vogelstein 1988, PMID 2841597). The durable insight is evolutionary selection: clones acquiring growth, survival and invasion advantages expand.

APC loss stabilizes β-catenin and dysregulates WNT-driven crypt proliferation. KRAS-pathway activation can promote growth in intermediate lesions; 18q/TGF-β pathway disruption and TP53 alteration are enriched later. TCGA confirmed recurrent changes across WNT, MAPK, PI3K, TGF-β and p53 systems while separating hypermutated and non-hypermutated tumors (Cancer Genome Atlas Network 2012, PMID 22810696).

Morphologic stage Common molecular tendency What the model does not prove
Normal crypt → early adenoma APC/WNT dysregulation That every adenoma has biallelic APC loss
Expanding adenoma RAS/MAPK and additional copy-number changes A fixed chronological order
Advanced adenoma Greater size, villous architecture or high-grade dysplasia Inevitable progression
Invasive cancer Invasion programs, TP53/TGF-β alterations, genomic complexity That late alteration caused invasion alone

Most adenomas do not become cancer. Size, villous component, high-grade dysplasia, multiplicity and proximal distribution are risk markers, but progression estimates are biased because clinically found lesions are removed.

Conventional adenoma morphology

Term Histology Risk implication
Tubular adenoma Predominantly tubular glands Common; risk rises with size, number and dysplasia
Tubulovillous adenoma Mixed tubular/villous Greater advanced-neoplasia association
Villous adenoma Predominantly villous architecture Higher-risk morphology
High-grade dysplasia Marked cytologic/architectural atypia without submucosal invasion Advanced precursor, not yet invasive cancer
Malignant polyp Invasive adenocarcinoma within an endoscopically removed polyp Requires depth, margin, grade, budding and lymphovascular-risk assessment

Terminology must not conflate high-grade dysplasia with invasive adenocarcinoma. Lymph-node risk begins with submucosal invasion and is modified by adverse histology.

Serrated pathway biology

Serrated lesions have a saw-toothed crypt contour, but subtype depends on the location and architecture of serration, crypt-base dilation/distortion and dysplasia. The modern categories are hyperplastic polyp, sessile serrated lesion and traditional serrated adenoma (Kim 2020, PMID 32580537).

Lesion Key morphology Typical biology Clinical issue
Hyperplastic polyp Serration mainly superficial; straight crypt bases Heterogeneous, often low malignant potential Large/proximal lesions can be misclassified SSLs
Sessile serrated lesion Basal crypt dilation, horizontal growth and distortion Often BRAF-mutant; CIMP progression Flat, mucus-capped and proximal; easily missed
SSL with dysplasia SSL plus conventional or serrated dysplasia Often advanced methylation; possible MLH1 loss May represent rapid transition toward cancer
Traditional serrated adenoma Villiform architecture, ectopic crypts, eosinophilic cytology KRAS or BRAF routes Less common; usually protuberant/distal

The BRAF–CIMP–MLH1 sequence provides a mechanistic bridge from an initially microsatellite-stable serrated lesion to sporadic MSI-high carcinoma (De Palma 2019, PMID 31330830; Bettington 2013, PMID 23339363). Not every BRAF-mutant serrated lesion becomes CIMP-high or loses MLH1.

Traditional serrated adenoma is molecularly heterogeneous and should not be treated as a small version of an SSL (McCarthy 2019, PMID 31413858).

Detection failure

Serrated lesions challenge colonoscopy because they can be flat, pale, mucus-covered and indistinct from surrounding folds. Pathology agreement also remains imperfect, especially between proximal hyperplastic polyps and SSLs (Langner 2015, PMID 25531494).

Detection is influenced by bowel preparation, withdrawal inspection, endoscopist adenoma/serrated detection, recognition of mucus caps, washing and complete examination. The proximal-colon contribution to interval cancers has made serrated detection a quality priority (Lindholm 2019, PMID 30407260).

Failure Observable quality signal Prevention response
Missed lesion Low adenoma or proximal serrated-polyp detection Training, adequate withdrawal and technique
Incomplete resection Residual tissue at scar Margin inspection, appropriate resection method, early site check when indicated
Pathology misclassification Variable SSL rates by pathologist Standard criteria and GI pathology review
Wrong surveillance interval Follow-up discordant with number/size/histology Structured reporting and recall systems
Failure to attend Overdue surveillance Navigation and reminder systems

Endoscopy quality measures—including preparation, cecal intubation, detection and complete excision—are linked components rather than independent boxes (Maida 2019, PMID 30614284). Higher adenoma detection is associated with lower post-colonoscopy cancer and mortality (Corley 2014, PMID 24693890).

Resection and residual risk

The National Polyp Study cohort associated colonoscopic polypectomy with a 53% reduction in colorectal-cancer mortality compared with expected population mortality over a median 15.8 years; the nonrandomized historical comparison limits causal precision (Zauber 2012, PMID 22356322).

Large registry cohorts show that risk after polypectomy depends strongly on baseline findings. In US cohorts, advanced adenoma was associated with higher subsequent colorectal-cancer risk, whereas nonadvanced adenoma and small serrated polyps had lower absolute risks (He 2020, PMID 31302144). Swedish linkage data similarly found persistent excess incidence/mortality for higher-risk groups rather than uniform normalization (Song 2020, PMID 32192628).

Baseline finding General risk direction after removal Surveillance implication
1–2 small tubular adenomas Lower Longer interval if high-quality complete exam
Multiple adenomas Higher with number Shorter interval; consider polyposis when burden is high
Adenoma ≥10 mm, villous or HGD Higher Shorter surveillance
SSL ≥10 mm or with dysplasia Higher Serrated-specific shorter surveillance
Piecemeal resection of large lesion Local residual/recurrence risk Early scar assessment
Numerous serrated lesions Possible serrated polyposis Specialized surveillance and family assessment

Observational surveillance studies show a gradient: patients with intermediate/high-risk adenomas benefit most clearly from follow-up, while low-risk groups may undergo excess colonoscopy for small absolute benefit (Atkin 2017, PMID 28457708; Coleman 2015, PMID 26082403). A meta-analysis of low-risk adenoma cohorts found incidence and mortality generally close to or below population comparators, but heterogeneity and surveillance contamination limit inference (Yang 2023, PMID 35350026).

Earlier population follow-up likewise found long-term risk remained stratified after adenoma removal, with advanced baseline features carrying greater excess risk than small low-grade lesions (Cottet 2012, PMID 22110052). These cohorts differ in colonoscopy era and follow-up intensity, so their absolute risks should not be transplanted directly into a modern program.

Large nonpedunculated lesions

Large lesions require optical assessment for deep invasion before resection. En-bloc excision improves histologic margin and invasion assessment; piecemeal EMR is effective for many benign large lesions but creates scar-recurrence surveillance needs.

Prospective follow-up after standardized endoscopic resection demonstrates that local recurrence is often endoscopically manageable when scars are checked systematically (Knabe 2014, PMID 24343549). Conversely, surveillance does not prevent every cancer in high-risk-polyp populations, reinforcing limits of test and system performance (Mouchli 2018, PMID 29491684).

Field effects and synchronous lesions

Adenoma multiplicity reflects a colon-wide susceptibility from age, exposure, inherited risk and local ecology. Synchronous lesions may carry distinct driver events; the largest lesion is not necessarily the only biologically relevant one.

“Field cancerization” is used for molecular or epigenetic change in histologically normal-appearing mucosa surrounding or distant from a tumor. Evidence supports altered fields; a targeted PubMed search updated through 2026-08-30 identified biomarker-development studies but no prospective outcome validation of a field assay as a replacement for complete-colon examination or established surveillance.

Interval and post-colonoscopy cancer

Post-colonoscopy colorectal cancer can result from:

  1. a missed precursor or cancer;
  2. incomplete precursor resection;
  3. incomplete examination or poor preparation;
  4. inappropriate surveillance delay;
  5. a lesion with genuinely rapid progression;
  6. miscoding or timing-definition artifacts.

Serrated molecular signatures are overrepresented among interval cancers, supporting but not proving a missed/rapid serrated route (Cisyk 2018, PMID 30121009). The interval-cancer label should trigger root-cause review rather than automatic attribution to biology.

Chemoprevention and pathway interception

Aspirin and other anti-inflammatory strategies have epidemiologic and trial evidence, but benefit–bleeding tradeoffs differ by baseline risk. The clearest long-duration randomized signal is in Lynch syndrome: CAPP2 found lower colorectal-cancer incidence after delayed follow-up among aspirin-assigned carriers, with dose optimization subsequently studied (Burn 2020, PMID 32534647).

No chemopreventive agent substitutes for endoscopic management of established high-risk precursors. Molecular prevention trials must separate reduction in adenoma recurrence from reduction in cancer and mortality.

The serrated pathway changed surveillance by making lesion subtype, size, location, number and dysplasia explicit rather than treating every nonadenomatous polyp as harmless (Kahi 2015, PMID 25556584). The remaining weakness is that surveillance recommendations have more observational than randomized outcome evidence.

Controversies

Controversy Evidence on one side Evidence on the other
Are SSLs fast-growing? Dysplastic SSLs can show abrupt molecular progression Most SSLs are indolent; observed rapidity may reflect prior miss
Is adenoma count causal? Multiplicity predicts future neoplasia Count also measures endoscopist detection and host field risk
Does surveillance save lives in low-risk adenoma? Removes metachronous lesions Absolute risk is low and randomized mortality evidence is sparse
Are interval cancers mainly serrated? Proximal/MSI/CIMP enrichment Incomplete resection and quality failures also contribute
Can molecular classifiers set intervals? Biology could refine morphology Prospective outcome validation is absent

Open questions

  • Which molecular or imaging markers identify the small subset of SSLs near transition to dysplasia? (Wang 2024, PMID 38515581)
  • Can proximal serrated-polyp detection be standardized as reliably as adenoma detection? (Lindholm 2019, PMID 30407260)
  • Which low-risk adenoma groups can safely leave colonoscopic surveillance and return to population screening? (Yang 2023, PMID 35350026)
  • How much post-colonoscopy cancer is attributable to miss, incomplete resection and genuinely rapid biology? (Cisyk 2018, PMID 30121009)
  • Can field-effect biomarkers predict metachronous neoplasia beyond baseline polyp features? (Sullivan 2022, PMID 35361330)

References

  1. Vogelstein B, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319(9):525-32. PMID 2841597
  2. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330-7. PMID 22810696
  3. O'Brien MJ, Zhao Q, Yang S. Colorectal serrated pathway cancers and precursors. Histopathology. 2015;66(1):49-65. PMID 25263173
  4. Zauber AG, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med. 2012;366(8):687-96. PMID 22356322
  5. He X, et al. Long-term Risk of Colorectal Cancer After Removal of Conventional Adenomas and Serrated Polyps. Gastroenterology. 2020;158(4):852-861.e4. PMID 31302144
  6. Sullivan BA, Noujaim M, Roper J. Cause, Epidemiology, and Histology of Polyps and Pathways to Colorectal Cancer. Gastrointest Endosc Clin N Am. 2022;32(2):177-194. PMID 35361330
  7. Kim JH, Kang GH. Evolving pathologic concepts of serrated lesions of the colorectum. J Pathol Transl Med. 2020;54(4):276-289. PMID 32580537
  8. De Palma FDE, et al. The Molecular Hallmarks of the Serrated Pathway in Colorectal Cancer. Cancers (Basel). 2019;11(7). PMID 31330830
  9. Bettington M, et al. The serrated pathway to colorectal carcinoma: current concepts and challenges. Histopathology. 2013;62(3):367-86. PMID 23339363
  10. McCarthy AJ, Serra S, Chetty R. Traditional serrated adenoma: an overview of pathology and emphasis on molecular pathogenesis. BMJ Open Gastroenterol. 2019;6(1):e000317. PMID 31413858
  11. Langner C. Serrated and non-serrated precursor lesions of colorectal cancer. Dig Dis. 2015;33(1):28-37. PMID 25531494
  12. Lindholm CR, Anderson JC, Srivastava A. The dark side of the colon: current issues surrounding the significance, prevalence, detection, diagnosis and management of serrated polyps. Curr Opin Gastroenterol. 2019;35(1):34-41. PMID 30407260
  13. Maida M, et al. Quality measures improving endoscopic screening of colorectal cancer: a review of the literature. Expert Rev Anticancer Ther. 2019;19(3):223-235. PMID 30614284
  14. Corley DA, et al. Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med. 2014;370(14):1298-306. PMID 24693890
  15. Song M, et al. Risk of colorectal cancer incidence and mortality after polypectomy: a Swedish record-linkage study. Lancet Gastroenterol Hepatol. 2020;5(6):537-547. PMID 32192628
  16. Atkin W, et al. Adenoma surveillance and colorectal cancer incidence: a retrospective, multicentre, cohort study. Lancet Oncol. 2017;18(6):823-834. PMID 28457708
  17. Coleman HG, et al. Colorectal Cancer Risk Following Adenoma Removal: A Large Prospective Population-Based Cohort Study. Cancer Epidemiol Biomarkers Prev. 2015;24(9):1373-80. PMID 26082403
  18. Yang X, et al. Incidence and Mortality of Post-Polypectomy Colorectal Cancer in Patients with Low-Risk Adenomas: A Systematic Review and Meta-Analysis of Observational Studies. Dig Dis. 2023;41(2):206-216. PMID 35350026
  19. Cottet V, et al. Long-term risk of colorectal cancer after adenoma removal: a population-based cohort study. Gut. 2012;61(8):1180-6. PMID 22110052
  20. Knabe M, et al. Standardized long-term follow-up after endoscopic resection of large, nonpedunculated colorectal lesions: a prospective two-center study. Am J Gastroenterol. 2014;109(2):183-9. PMID 24343549
  21. Mouchli MA, et al. Colonoscopy surveillance for high risk polyps does not always prevent colorectal cancer. World J Gastroenterol. 2018;24(8):905-916. PMID 29491684
  22. Cisyk AL, et al. Characterizing Microsatellite Instability and Chromosome Instability in Interval Colorectal Cancers. Neoplasia. 2018;20(9):943-950. PMID 30121009
  23. Burn J, et al. Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Lancet. 2020;395(10240):1855-1863. PMID 32534647
  24. Kahi CJ. How does the serrated polyp pathway alter CRC screening and surveillance? Dig Dis Sci. 2015;60(3):773-80. PMID 25556584
  25. Wang JD, et al. The histologic features, molecular features, detection and management of serrated polyps: a review. Front Oncol. 2024;14:1356250. PMID 38515581